Mechanisms of neurotransmitter transport and drug inhibition in human VMAT2.
Humans
Adrenergic Uptake Inhibitors
/ chemistry
Biological Transport
/ drug effects
Cryoelectron Microscopy
Neurotransmitter Agents
/ chemistry
Reserpine
/ chemistry
Serotonin
/ metabolism
Synaptic Transmission
Tetrabenazine
/ chemistry
Vesicular Monoamine Transport Proteins
/ antagonists & inhibitors
Substrate Specificity
/ drug effects
Journal
Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
16
06
2023
accepted:
09
10
2023
medline:
1
12
2023
pubmed:
2
11
2023
entrez:
2
11
2023
Statut:
ppublish
Résumé
Monoamine neurotransmitters such as dopamine and serotonin control important brain pathways, including movement, sleep, reward and mood
Identifiants
pubmed: 37914936
doi: 10.1038/s41586-023-06727-9
pii: 10.1038/s41586-023-06727-9
doi:
Substances chimiques
Adrenergic Uptake Inhibitors
0
Neurotransmitter Agents
0
Reserpine
8B1QWR724A
Serotonin
333DO1RDJY
SLC18A2 protein, human
0
Tetrabenazine
Z9O08YRN8O
Vesicular Monoamine Transport Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1086-1092Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Kandel, E. R., Koester, J. D., Mack, S. H. & Siegelbaum, S. A. Principles of Neural Science 6th edn (McGraw Hill Professional, 2021).
Ng, J., Papandreou, A., Heales, S. J. & Kurian, M. A. Monoamine neurotransmitter disorders—clinical advances and future perspectives. Nat. Rev. Neurol. 11, 567–584 (2015).
pubmed: 26392380
doi: 10.1038/nrneurol.2015.172
Eiden, L. E. & Weihe, E. VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse. Ann. N.Y. Acad. Sci. 1216, 86–98 (2011).
pubmed: 21272013
pmcid: 4183197
doi: 10.1111/j.1749-6632.2010.05906.x
Schuldiner, S., Shirvan, A. & Linial, M. Vesicular neurotransmitter transporters: from bacteria to humans. Physiol. Rev. 75, 369–392 (1995).
pubmed: 7724667
doi: 10.1152/physrev.1995.75.2.369
Yaffe, D., Forrest, L. R. & Schuldiner, S. The ins and outs of vesicular monoamine transporters. J. Gen. Physiol. 150, 671–682 (2018).
pubmed: 29666153
pmcid: 5940252
doi: 10.1085/jgp.201711980
Wimalasena, K. Vesicular monoamine transporters: structure–function, pharmacology, and medicinal chemistry. Med. Res. Rev. 31, 483–519 (2011).
pubmed: 20135628
doi: 10.1002/med.20187
Davis, M. C., Miller, B. J., Kalsi, J. K., Birkner, T. & Mathis, M. V. Efficient trial design—FDA approval of valbenazine for tardive dyskinesia. N. Engl. J. Med. 376, 2503–2506 (2017).
pubmed: 28489481
doi: 10.1056/NEJMp1704898
Huntington Study Group. Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial. J. Am. Med. Assoc. 316, 40–50 (2016).
doi: 10.1001/jama.2016.8655
Siddiqui, M., Bhatt, H., Judd, E. K., Oparil, S. & Calhoun, D. A. Reserpine substantially lowers blood pressure in patients with refractory hypertension: a proof-of-concept study. Am. J. Hypertens. 33, 741–747 (2020).
pubmed: 32179903
pmcid: 7402229
doi: 10.1093/ajh/hpaa042
Takahashi, N. et al. VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc. Natl Acad. Sci. USA 94, 9938–9943 (1997).
pubmed: 9275230
pmcid: 23302
doi: 10.1073/pnas.94.18.9938
Wang, Y.-M. et al. Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine. Neuron 19, 1285–1296 (1997).
pubmed: 9427251
doi: 10.1016/S0896-6273(00)80419-5
Fon, E. A. et al. Vesicular transport regulates monoamine storage and release but is not essential for amphetamine action. Neuron 19, 1271–1283 (1997).
pubmed: 9427250
doi: 10.1016/S0896-6273(00)80418-3
Saida, K. et al. Brain monoamine vesicular transport disease caused by homozygous SLC18A2 variants: a study in 42 affected individuals. Genet. Med. 25, 90–102 (2023).
pubmed: 36318270
doi: 10.1016/j.gim.2022.09.010
Drew, D. & Boudker, O. Shared molecular mechanisms of membrane transporters. Annu. Rev. Biochem. 85, 543–572 (2016).
pubmed: 27023848
doi: 10.1146/annurev-biochem-060815-014520
Drew, D., North, R. A., Nagarathinam, K. & Tanabe, M. Structures and general transport mechanisms by the major facilitator superfamily (MFS). Chem. Rev. 121, 5289–5335 (2021).
pubmed: 33886296
pmcid: 8154325
doi: 10.1021/acs.chemrev.0c00983
Yan, N. Structural biology of the major facilitator superfamily transporters. Annu. Rev. Biophys. 44, 257–283 (2015).
pubmed: 26098515
doi: 10.1146/annurev-biophys-060414-033901
Parsons, S. M. Transport mechanisms in acetylcholine and monoamine storage. FASEB J. 14, 2423–2434 (2000).
pubmed: 11099460
doi: 10.1096/fj.00-0203rev
Erickson, J. D., Eiden, L. E. & Hoffman, B. J. Expression cloning of a reserpine-sensitive vesicular monoamine transporter. Proc. Natl Acad. Sci. USA 89, 10993–10997 (1992).
pubmed: 1438304
pmcid: 50469
doi: 10.1073/pnas.89.22.10993
Liu, Y. et al. A cDNA that suppresses MPP
pubmed: 1505023
doi: 10.1016/0092-8674(92)90425-C
Weihe, E., Schäfer, M. K., Erickson, J. D. & Eiden, L. E. Localization of vesicular monoamine transporter isoforms (VMAT1 and VMAT2) to endocrine cells and neurons in rat. J. Mol. Neurosci. 5, 149–164 (1994).
pubmed: 7654518
doi: 10.1007/BF02736730
Peter, D. et al. Differential expression of two vesicular monoamine transporters. J. Neurosci. 15, 6179–6188 (1995).
pubmed: 7666200
pmcid: 6577657
doi: 10.1523/JNEUROSCI.15-09-06179.1995
Erickson, J. D. & Eiden, L. E. Functional identification and molecular cloning of a human brain vesicle monoamine transporter. J. Neurochem. 61, 2314–2317 (1993).
pubmed: 8245983
doi: 10.1111/j.1471-4159.1993.tb07476.x
Nikkhah, A. A brief review on the role of vesicular monoamine transporter2 inhibitors in hyperkinetic movement disorders. Iran. J. Child Neurol. 15, 29–33 (2021).
pubmed: 34282360
pmcid: 8272547
Chen, J. J., Ondo, W. G., Dashtipour, K. & Swope, D. M. Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature. Clin. Ther. 34, 1487–1504 (2012).
pubmed: 22749259
doi: 10.1016/j.clinthera.2012.06.010
Harriott, N. D., Williams, J. P., Smith, E. B., Bozigian, H. P. & Grigoriadis, D. E. VMAT2 inhibitors and the path to Ingrezza (valbenazine). Prog. Med. Chem. 57, 87–111 (2018).
pubmed: 29680151
doi: 10.1016/bs.pmch.2017.12.002
Weir, M. R. Reserpine: a new consideration of an old drug for refractory hypertension. Am. J. Hypertens. 33, 708–710 (2020).
pubmed: 32303749
pmcid: 7402223
doi: 10.1093/ajh/hpaa069
Fraser, H. S. Reserpine: a tragic victim of myths, marketing, and fashionable prescribing. Clin. Pharmacol. Ther. 60, 368–373 (1996).
pubmed: 8873684
doi: 10.1016/S0009-9236(96)90193-9
Lobay, D. Rauwolfia in the treatment of hypertension. Integr. Med. 14, 40–46 (2015).
Scherman, D. & Henry, J. P. Reserpine binding to bovine chromaffin granule membranes. Characterization and comparison with dihydrotetrabenazine binding. Mol. Pharmacol. 25, 113–122 (1984).
pubmed: 6708929
Darchen, F., Scherman, D. & Henry, J. P. Reserpine binding to chromaffin granules suggests the existence of two conformations of the monoamine transporter. Biochemistry 28, 1692–1697 (1989).
pubmed: 2719928
doi: 10.1021/bi00430a040
Schuldiner, S., Liu, Y. & Edwards, R. H. Reserpine binding to a vesicular amine transporter expressed in Chinese hamster ovary fibroblasts. J. Biol. Chem. 268, 29–34 (1993).
pubmed: 8416935
doi: 10.1016/S0021-9258(18)54110-7
Liu, Y. & Edwards, R. H. The role of vesicular transport proteins in synaptic transmission and neural degeneration. Annu. Rev. Neurosci. 20, 125–156 (1997).
pubmed: 9056710
doi: 10.1146/annurev.neuro.20.1.125
Peter, D., Jimenez, J., Liu, Y., Kim, J. & Edwards, R. H. The chromaffin granule and synaptic vesicle amine transporters differ in substrate recognition and sensitivity to inhibitors. J. Biol. Chem. 269, 7231–7237 (1994).
pubmed: 8125935
doi: 10.1016/S0021-9258(17)37272-1
Støve, S. I., Skjevik, Å. A., Teigen, K. & Martinez, A. Inhibition of VMAT2 by β
pubmed: 36418492
pmcid: 9684503
doi: 10.1038/s42003-022-04121-1
Ugolev, Y., Segal, T., Yaffe, D., Gros, Y. & Schuldiner, S. Identification of conformationally sensitive residues essential for inhibition of vesicular monoamine transport by the noncompetitive inhibitor tetrabenazine. J. Biol. Chem. 288, 32160–32171 (2013).
pubmed: 24062308
pmcid: 3820856
doi: 10.1074/jbc.M113.502971
Kanner, B. I., Fishkes, H., Maron, R., Sharon, I. & Schuldiner, S. Reserpine as a competitive and reversible inhibitor of the catecholamine transporter of bovine chromaffin granules. FEBS Lett. 100, 175–178 (1979).
pubmed: 437101
doi: 10.1016/0014-5793(79)81158-8
Erickson, J. D., Schafer, M. K., Bonner, T. I., Eiden, L. E. & Weihe, E. Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proc. Natl Acad. Sci. USA 93, 5166–5171 (1996).
pubmed: 8643547
pmcid: 39426
doi: 10.1073/pnas.93.10.5166
Yaffe, D., Vergara-Jaque, A., Forrest, L. R. & Schuldiner, S. Emulating proton-induced conformational changes in the vesicular monoamine transporter VMAT2 by mutagenesis. Proc. Natl Acad. Sci. USA 113, E7390–E7398 (2016).
pubmed: 27821772
pmcid: 5127352
doi: 10.1073/pnas.1605162113
Steiner-Mordoch, S., Shirvan, A. & Schuldiner, S. Modification of the pH profile and tetrabenazine sensitivity of rat VMAT1 by replacement of aspartate 404 with glutamate. J. Biol. Chem. 271, 13048–13054 (1996).
pubmed: 8662678
doi: 10.1074/jbc.271.22.13048
Merickel, A., Kaback, H. R. & Edwards, R. H. Charged residues in transmembrane domains II and XI of a vesicular monoamine transporter form a charge pair that promotes high affinity substrate recognition. J. Biol. Chem. 272, 5403–5408 (1997).
pubmed: 9038139
doi: 10.1074/jbc.272.9.5403
Merickel, A., Rosandich, P., Peter, D. & Edwards, R. H. Identification of residues involved in substrate recognition by a vesicular monoamine transporter. J. Biol. Chem. 270, 25798–25804 (1995).
pubmed: 7592763
doi: 10.1074/jbc.270.43.25798
Yaffe, D., Radestock, S., Shuster, Y., Forrest, L. R. & Schuldiner, S. Identification of molecular hinge points mediating alternating access in the vesicular monoamine transporter VMAT2. Proc. Natl Acad. Sci. USA 110, E1332–E1341 (2013).
pubmed: 23530208
pmcid: 3625309
doi: 10.1073/pnas.1220497110
Yaffe, D. et al. Functionally important carboxyls in a bacterial homologue of the vesicular monoamine transporter (VMAT). J. Biol. Chem. 289, 34229–34240 (2014).
pubmed: 25336661
pmcid: 4256354
doi: 10.1074/jbc.M114.607366
Chen, H. et al. Structural and functional insights into Spns2-mediated transport of sphingosine-1-phosphate. Cell 186, 2644–2655 (2023).
pubmed: 37224812
doi: 10.1016/j.cell.2023.04.028
Binz, H. K. et al. High-affinity binders selected from designed ankyrin repeat protein libraries. Nat. Biotechnol. 22, 575–582 (2004).
pubmed: 15097997
doi: 10.1038/nbt962
Hu, G. et al. New fluorescent substrate enables quantitative and high-throughput examination of vesicular monoamine transporter 2 (VMAT2). ACS Chem. Biol. 8, 1947–1954 (2013).
pubmed: 23859623
pmcid: 4557792
doi: 10.1021/cb400259n
Weaver, J. A. & Deupree, J. D. Conditions required for reserpine binding to the catecholamine transporter on chromaffin granule ghosts. Eur. J. Pharmacol. 80, 437–438 (1982).
pubmed: 7106194
doi: 10.1016/0014-2999(82)90093-0
Stern-Bach, Y., Greenberg-Ofrath, N., Flechner, I. & Schuldiner, S. Identification and purification of a functional amine transporter from bovine chromaffin granules. J. Biol. Chem. 265, 3961–3966 (1990).
pubmed: 2303487
doi: 10.1016/S0021-9258(19)39688-7
Rudnick, G., Steiner-Mordoch, S. S., Fishkes, H., Stern-Bach, Y. & Schuldiner, S. Energetics of reserpine binding and occlusion by the chromaffin granule biogenic amine transporter. Biochemistry 29, 603–608 (1990).
pubmed: 2140052
doi: 10.1021/bi00455a002
Goehring, A. et al. Screening and large-scale expression of membrane proteins in mammalian cells for structural studies. Nat. Protoc. 9, 2574–2585 (2014).
pubmed: 25299155
pmcid: 4291175
doi: 10.1038/nprot.2014.173
Kawate, T. & Gouaux, E. Fluorescence-detection size-exclusion chromatography for precrystallization screening of integral membrane proteins. Structure 14, 673–681 (2006).
pubmed: 16615909
doi: 10.1016/j.str.2006.01.013
Bolte, S. & Cordelières, F. P. A guided tour into subcellular colocalization analysis in light microscopy. J. Microsc. 224, 213–232 (2006).
pubmed: 17210054
doi: 10.1111/j.1365-2818.2006.01706.x
Rana, M. S., Wang, X. & Banerjee, A. An improved strategy for fluorescent tagging of membrane proteins for overexpression and purification in mammalian cells. Biochemistry 57, 6741–6751 (2018).
pubmed: 30481009
doi: 10.1021/acs.biochem.8b01070
Zheng, S. Q. et al. MotionCor2—anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat. Methods 14, 331–332 (2017).
pubmed: 28250466
pmcid: 5494038
doi: 10.1038/nmeth.4193
Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290–296 (2017).
pubmed: 28165473
doi: 10.1038/nmeth.4169
Bepler, T. et al. Positive-unlabeled convolutional neural networks for particle picking in cryo-electron micrographs. Nat. Methods 16, 1153–1160 (2019).
pubmed: 31591578
pmcid: 6858545
doi: 10.1038/s41592-019-0575-8
Punjani, A., Zhang, H. & Fleet, D. J. Non-uniform refinement: adaptive regularization improves single-particle cryo-EM reconstruction. Nat. Methods 17, 1214–1221 (2020).
pubmed: 33257830
doi: 10.1038/s41592-020-00990-8
Zivanov, J. et al. New tools for automated high-resolution cryo-EM structure determination in RELION-3. eLife 7, e42166 (2018).
pubmed: 30412051
pmcid: 6250425
doi: 10.7554/eLife.42166
Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583–589 (2021).
pubmed: 34265844
pmcid: 8371605
doi: 10.1038/s41586-021-03819-2
Pettersen, E. F. et al. UCSF Chimera—a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605–1612 (2004).
pubmed: 15264254
doi: 10.1002/jcc.20084
Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D 66, 486–501 (2010).
pubmed: 20383002
pmcid: 2852313
doi: 10.1107/S0907444910007493
Croll, T. I. ISOLDE: a physically realistic environment for model building into low-resolution electron-density maps. Acta Crystallogr. D 74, 519–530 (2018).
doi: 10.1107/S2059798318002425
Afonine, P. V. et al. Real-space refinement in PHENIX for cryo-EM and crystallography. Acta Crystallogr. D 74, 531–544 (2018).
doi: 10.1107/S2059798318006551
Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D 66, 12–21 (2010).
pubmed: 20057044
doi: 10.1107/S0907444909042073
Goddard, T. D. et al. UCSF ChimeraX: meeting modern challenges in visualization and analysis. Protein Sci. 27, 14–25 (2018).
pubmed: 28710774
doi: 10.1002/pro.3235
Black, C. A. et al. Assessing vesicular monoamine transport and toxicity using fluorescent false neurotransmitters. Chem. Res. Toxicol. 34, 1256–1264 (2021).
pubmed: 33378168
doi: 10.1021/acs.chemrestox.0c00380